FDA Approval of Zanubrutinib (ALPINE & SEQUOIA Study)

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the SEQUOIA trial investigating zanubrutinib vs bendamustine-rituximab in first-line CLL/SLL.

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Mazyar Shadman, MD, MPH, to discuss the ALPINE study looking at zanubrutinib vs ibrutinib in relapsed or refractory CLL.

A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.